Outcomes in patients with nontriple antiphospholipid syndrome (APS) anticoagulated with rivaroxaban

被引：1
|
作者：
Htut, Thura Win [1 ]
Milne, Denis [1 ]
Khan, Mohammed M. [1 ]
Watson, Henry G. [1 ]
机构：
[1] Aberdeen Royal Infirm, Dept Haematol, Foresterhill Hlth Campus, Aberdeen, Scotland
来源：
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2021年 / 43卷 / 05期
关键词：
anticoagulation; antiphospholipid syndrome; rivaroxaban; venous thromboembolism; warfarin; THROMBOSIS; WARFARIN;
D O I：
10.1111/ijlh.13464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E252 / E253
页数：2
相关论文
共 50 条
  • [31] Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?
    Salma Siddique
    Jessie Risse
    Guillaume Canaud
    Stéphane Zuily
    Current Rheumatology Reports, 2017, 19
  • [32] Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome
    Moll, Stephan
    ANNALS OF INTERNAL MEDICINE, 2020, 172 (07) : 510 - 510
  • [33] Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation
    Yao, Xiaoxi
    Tangri, Navdeep
    Gersh, Bernard J.
    Sangaralingham, Lindsey R.
    Shah, Nilay D.
    Nath, Karl A.
    Noseworthy, Peter A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (21) : 2621 - 2632
  • [34] Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS)
    Woller, Scott C.
    Stevens, Scott M.
    Kaplan, David A.
    Branch, D. Ware
    Aston, Valerie T.
    Wilson, Emily L.
    Gallo, Heather M.
    Johnson, Eric G.
    Rondina, Matthew T.
    Lloyd, James F.
    Evans, R. Scott
    Elliott, C. Gregory
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2016, 22 (03) : 239 - 247
  • [35] Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?
    Siddique, Salma
    Risse, Jessie
    Canaud, Guillaume
    Zuily, Stephane
    CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (10)
  • [36] Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome
    Yagi, Shusuke
    Nishiyama, Seiichi
    Abe, Toshio
    Sata, Masataka
    BMJ CASE REPORTS, 2019, 12 (01)
  • [37] Traditional risk factors for cardiovascular disease in primary antiphospholipid syndrome (APS) when compared with secondary APS: a study with 96 patients
    Ribeiro, A. R.
    Carvalho, J. F.
    ACTA REUMATOLOGICA PORTUGUESA, 2010, 35 (01): : 36 - 41
  • [38] Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry')
    Erton, Zeynep Belce
    Sevim, Ecem
    de Jesus, Guilherme Ramires
    Cervera, Ricard
    Ji, Lanlan
    Pengo, Vittorio
    Ugarte, Amaia
    Andrade, Danieli
    Andreoli, Laura
    Atsumi, Tatsuya
    Fortin, Paul R.
    Gerosa, Maria
    Zuo, Yu
    Petri, Michelle
    Sciascia, Savino
    Tektonidou, Maria G.
    Aguirre-Zamorano, Maria Angeles
    Branch, D. Ware
    Erkan, Doruk
    LUPUS SCIENCE & MEDICINE, 2022, 9 (01):
  • [39] Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
    Coleman, Craig I.
    Beyer-Westendorf, Jan
    Bunz, Thomas J.
    Mahan, Charles E.
    Spyropoulos, Alex C.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (04) : 575 - 582
  • [40] Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
    Kirchhof, Paulus
    Haas, Sylvia
    Amarenco, Pierre
    Hess, Susanne
    Lambelet, Marc
    van Eickels, Martin
    Turpie, Alexander G. G.
    Camm, A. John
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (05):
12345